

**WORLD LEADING
ONE-STOP PLATFORM
FROM SBDD
TO COMMERCIAL
DRUG DELIVERY**

**从早期基于结构的药物研发
到商业化药物交付的一站式综合服务平台**

从早期基于结构的药物研发到 商业化药物交付的一站式综合服务平台


World Leading One-Stop Platform from SBDD to Commercial Drug Delivery



VIVA BIOTECH HOLDINGS (01873.HK)

成立于2008年，向全球创新药研发企业提供从早期基于结构的药物研发到商业化药物交付的一站式综合服务。凭借在基于结构的药物研发（SBDD）技术领域的领先优势，我们向全球合作伙伴提供新药研究阶段的CRO服务，搭建了X射线蛋白晶体技术、冷冻电镜技术（Cryo-EM）、亲和力质谱筛选技术（ASMS）、表面等离子共振技术（SPR）、氘气交换质谱技术（HDX-MS）、计算机辅助药物设计等多个先进技术平台及专家团队。通过子公司朗华制药，我们提供从临床前开发到商业化生产的一站式CMC/CDMO解决方案。同时，我们专注于发现、投资高潜力生物医药初创公司，以独创的技术服务换取股权（EFS）的商业模式，解决未满足的临床需求。

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.



作为维亚生物的子公司，是一家高速成长中的药物研发与生产企业，致力于为全球合作伙伴提供小分子药物从原料药（API）到制剂，从临床前到商业化供应，覆盖药物全生命周期的高效、灵活、高质量的CDMO一站式解决方案。

Langhua Pharmaceutical, a subsidiary of Viva Biotech Holdings, is a comprehensive pharmaceutical company engaged in drug research, development, and production. Langhua offers our worldwide partners One-Stop CDMO solution in new drugs' entire full life-cycle for small molecule Active Pharmaceutical Ingredients (API) and Finished Dosage Form, from preclinical to commercial supply.



作为维亚生物的子公司，是一家小分子药物研发服务提供商，主要提供高端的药物化学和合成化学服务。与客户进行全方位合作，信实研发团队可以融入到客户公司的药物研发项目中，提升项目的研发能力和洞察力，从靶点活性化合物到先导化合物的发现及优化以及临床前候选药物的选定等阶段加速客户的科研项目进程。

SYNthesis, a subsidiary of Viva Biotech Holdings, is a provider of small molecule drug discovery services. Their focus is on the provision of world class medicinal and synthetic chemistry. Synthesis fit seamlessly into a client' s company to add capacity and insight to their drug discovery programs, and work with your scientists to accelerate programs from hit-to-lead through to lead optimisation and beyond.

CRO药物研发服务

世界领先的基于结构的药物研发服务 (SBDD)

生物物理技术

Biophysical Technology

PROTAC技术平台

PROTAC Platform

研究超50个E3 ligase
Researched over 50 E3 ligases

交付超100个靶蛋白-PROTAC-E3 ligase三元复合结构
Delivered 100+ target proteins-PROTAC-E3 ligase ternary complex structures

膜蛋白研究技术

Membrane Protein Targeted Discovery Technology

专有的GPCR/Ion Channels/ Transporters研发技术平台

Proprietary Technology in GPCR/ Ion Channels/ Transporters

药物化学

Medicinal Chemistry

化学合成、基于结构的药化设计

Chemical synthesis, Structure guided compound design

药物筛选技术

Hit Discovery Technology

HTS, ASMS, Intact-MS, SPR, Crystal Soaking, TSA, VS

药代动力学

Pharmacokinetics

ADME/PK

蛋白生产制备与结构研究

Protein Production & Structural Biology

世界领先、效率最高、规模最大的蛋白研究平台
World-class and largest in operation

Bioassay平台

Bioassay Platforms

分子与细胞水平检测

Biochemical and cell based assays with advanced technologies

治疗性抗体发现技术平台

Therapeutic Antibody Discovery

杂交瘤技术、噬菌体展示技术、哺乳细胞展示技术

Hybridoma, Phage Display, Mammalian Display

CRO Drug R&D Services

World's Leading Structure-Based Drug Discovery (SBDD) Services

冷冻电镜技术平台

Cryo-EM Technology

单颗粒分析技术、微晶电子衍射技术
Single-particle Analysis, Micro-crystal Electron Diffraction

原子分辨率结构解析

Near-atomic resolution 3D Structures Analysis

计算机辅助药物设计平台

Computer-Aided Drug Design

计算化学、计算生物

Computational Chemistry Technology, Computational Biology Technology

CDMO研发生产服务

小分子药物研发、生产一站式CDMO服务

原料药服务

API Services

路线设计与筛选

Synthetic route design and selection

工艺开发及优化

Process development & optimization

毒理批生产

Tox batch manufacturing

分析方法开发及验证

API analytical method development and validation

稳定性研究

API stability study

GMP条件下临床样品生产 (Phase I~III)

GMP manufacturing for Phase I, II, and III clinical trials

放大生产到商业化 (毫克~1000吨)

Scale-up and commercial manufacturing (mg to 1000 ton)

eCTD申报资料准备 (支持NMPA、FDA、IND/NDA)

API CTD document preparation for NMPA, FDA, IND, and NDA filings

制剂服务

Drug Product Services

制剂处方前研究

Pre-formulation study

制剂处方、工艺开发和放大

Formulation & process development

Non-GMP中试批的生产

Non-GMP Pilot Scale Production

分析方法开发及验证

DP analytical method development and validation

多种常用剂型及缓释制剂开发

Various dosage form developments

稳定性研究

DP stability study

GMP条件下临床样品生产 (Phase I~II)

GMP manufacturing for Phase I and II clinical trials

eCTD申报资料准备 (支持NMPA、FDA、IND/NDA)

DP CTD document preparation for NMPA, FDA, IND, and NDA filings

CDMO R&D and Production Services

One-Stop Solution for Small Molecule Drug CDMO



■ CRO药物研发服务

CRO Drug R&D Services



48,925+

累计交付蛋白结构

Delivering protein structures in total



1,878+

研发独立药物靶标

Independent drug targets researched and developed



1,617 人

科学家及研发人员

Scientists and technicians



维亚生物以基于结构的药物研发 (SBDD) 领域的优势, 为全球生物科技及制药客户的临床前阶段创新药开发提供全球领先的药物研发服务。服务涵盖客户对早期药物研发的全方位需求, 包括靶标蛋白的表达与结构研究、药物筛选、抗体发现与表达制备、药物活性测试、计算机辅助药物设计、药物化学设计与合成、药物的 ADME 及 PK 研究直到确定临床候选化合物。

With its leading position in Structure-Based Drug Discovery (SBDD), Viva provides state-of-the-art drug research and development services to global biotechnology and pharmaceutical clients for their preclinical, innovative drug discovery programs. We cover the all-around needs of our clients for their early drug research and development, including protein expression, purification and structure determination, hits screening, therapeutic antibody discovery, antibody expression and production, Bioassay, computer-aided drug design, medicinal chemistry and custom synthesis, ADME, and PK studies.

药研生物技术服务

Discovery Biology Services

为全球客户高效开展药物筛选、药物作用机理研究、基于结构的药物发现及基于片段的药物发现等赋能，加速推进创新药研发进程、降低研发成本。

We efficiently carry out Hit screening, MOA study, Structure-Based Drug Discovery, and Fragment-Based Drug Discovery for global clients, and accelerate innovative drug discovery and development while reducing R&D costs.

国际一流的药物筛选技术平台

Hit Discovery Platform

多样性化合物库筛选技术

HTS、ASMS亲和力筛选、虚拟筛选

Diverse Library Screening Technologies: HTS, ASMS, VS

片段化合物库筛选技术

晶体浸泡、SPR、ASMS、TSA、虚拟筛选

Fragment Library Screening Technologies: Crystal Soaking, SPR, ASMS, TSA, VS

共价化合物库筛选技术

Covalent Library Screening Technologies: Intact-MS

化合物库

多个片段化合物库、GPCR化合物库、多样性化合物库

Compound Library: Multiple Fragment Library, GPCR-Focused Library, Diverse Library with 200K Compounds

全面的生物物理技术服务平台(药物MOA研究)

Biophysical Technology

蛋白结构研究

Protein Structural Study: X-ray, Cryo-EM (SPA、Micro-ED)

结合位点研究

Binding Site Study: HDX-MS

非共价结合与结合分子比例研究

Non-Covalent Binding Proportion Study: Native-MS

非共价结合鉴定与筛选

Non-Covalent Binding Identification and Screening: ASMS, Thermal Shift Assay (TSA), SPR

非共价动力学研究: SPR

Non-Covalent Kinetic Study: SPR

共价结合鉴定与筛选

Covalent Binding Identification and Screening: Intact-MS

共价动力学研究

Covalent Kinetic Study: Intact-MS

共价化合物结合位点鉴定

Covalent Binding Site Identification: peptide mapping MS

化学服务

Chemistry Services

与药研生物技术服务高效协同，专注于全方位、高质量、个性化的化学服务，并将特色的计算机辅助药物设计（CADD）平台与药物化学相结合，以支持药物化学设计工作。拥有一支极具原创药物设计经验的药化团队，具备多种计算化学方法开发能力，可提供化学药与蛋白药物 CADD 及方法开发，特色的增强分子动力学取样及特色的自由能计算服务等。

Our chemistry services are highly synergized with our discovery biology services and supported by a computer-aided drug design platform, combined with medicinal chemistry to support design efforts. Our medicinal chemistry team has strong experience in innovative drug design and multiple computational chemistry methods to provide CADD and method development for chemical and protein drugs, featured enhanced molecular dynamics sampling and free energy calculations, and much more.

药物化学

Medicinal Chemistry

苗头化合物发现和拓展、基于结构和活性的化合物设计

Discovery and Optimization of Hit Compounds, Structure and SAR guided Compound Design

合成化学

Synthetic Chemistry

合成路线设计、化合物库、非GMP公斤级放大

Synthetic Route Design, Compound Library, Non-GMP Kilo Scale-Up

分析制备

Analytical Chemistry and Purification Preparation

LCMS、HPLC、核磁、手性化合物分析和拆分
LCMS, HPLC, 1D and 2D NMR Analysis, Chiral Synthesis and Separation

化合物类型

Compound Types

大环化合物、杂环化合物、PROTAC、核苷酸、多肽、氘代化合物

Macrocyclic Compounds, Heterocyclic Compounds, PROTAC, Nucleotides, Peptides, Deuterium Containing Compounds

技术平台

Technology Platform

催化反应筛选、多肽合成、光催化、同位素修饰等

Catalytic Screening Technology, Polypeptide Technology, Light-catalyzed Reaction, Isotope Modification, and much more

大分子药物研发服务

Antibody Drug R&D Services

拥有一支专业的大分子研发团队（硕士及以上占比70%），通过成熟的抗体发现平台，应用杂交瘤、噬菌体展示人天然抗体库、哺乳细胞展示、免疫羊驼、骆驼纳米抗体、兔单克隆抗体等多个核心技术，为全球客户提供从靶标抗原到候选功能性抗体的大分子研发一站式服务。

We have a high-level professional team (70% of which have masters and above) focused on preclinical Antibody drug discovery. We have various antibody discovery platforms such as hybridoma, phage display, mammalian display, immunized alpaca or camel nano antibody, rabbit monoclonal antibody, and more. We provide one-stop services in Antibody R&D from target antigens to functional antibody candidates for domestic and international pharmaceutical and biotechnology companies.

抗原设计、制备与活性验证

Antigen Design, Preparation, and Identification

多物种单克隆抗体发现

Discovery of Multi-species Monoclonal Antibodies

抗体功能性筛选与鉴定

Functional Screening and Identification of Antibodies

抗体工程改造

Antibody Engineering Transformation

抗体体外药效评价

Antibody Efficacy Evaluation In Vitro

PROTAC药物研发服务

PROTAC Drug R&D Services

蛋白制备与三元体系结构研究（X-ray&CryoEM，>50个E3 ligase，>100个靶蛋白-PROTAC-E3连接酶三元复合结构）

Protein Preparation and Ternary Complex Structure Determination (X-ray & Cryo-EM, >50 E3 ligases, >100 target protein-PROTAC-E3 ligase ternary complex structures)

PROTAC分子筛选（ASMS、SPR、晶体浸泡等）

Screening for Molecule Glues and Novel E3 Ligase Ligands (ASMS, SPR, Crystal Soaking, etc.)

PROTAC三元体系动力学研究

PROTAC Ternary Complex Kinetics (SPR)

PROTAC分子活性检测

PROTAC Degradation Assays and Ternary Complex Assays

PROTAC分子设计与合成

PROTAC Molecule Design and Synthesis

PROTAC分子药物代谢研究

ADME & PK/PD Studies of PROTAC Molecules

计算机辅助PROTAC分子设计

Computer-Aided PROTAC Design

CDMO研发生产服务

CDMO R&D and Production Services

维亚生物子公司朗华制药致力于为全球合作伙伴提供从原料药到制剂，从临床前到商业化供应，覆盖药物全生命周期的高效、灵活、高质量的一站式CDMO解决方案。

As the subsidiary of Viva Biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drugs' entire full life-cycle for small molecule Active Pharmaceutical Ingredients (API) and Finished Dosage Form, from pre-clinical to commercial supply.



860m³+

产能

Production capacity



13,000m²

实验室面积

Laboratory area



300+

科学家及研究人员

Scientists and R&D staff



852家

合作客户

Clients

一站式CMC/CDMO服务能力

One-stop CMC/CDMO Service Capability

化学原料药 & 制剂，研发、生产一体化服务：在上海、台州、宁波设有三个研发中心，超过15年与国际制药大公司合作经验。

Langhua operates three R&D centers in Shanghai, Ningbo, and Taizhou; 15+ years of experience in collaboration with major international pharmaceutical companies.

从CMC研究、中美双报IND申报、临床阶段GMP样品生产、NDA申报到商业化生产支持。

From CMC research, Sino-US dual IND filing, clinical supply manufacturing under GMP condition, and NDA application to commercial product manufacturing.

满足全球标准的GMP、EHS体系

GMP and EHS Compliance

生产基地通过多个官方GMP认证

Our factories have multiple GMP certifications:

•获得11个证书 (US-DMF、EU-GMP证书、WHO-PO证书、CEP证书)

11 Certificates (US-DMF, EU-GMP, WHO-PQ, CEP)

•14次通过FDA、EDQM、WHO、ANVISA、PMDA、NMPA等审计

14 Passed Inspections (FDA, EDQM, WHO, ANVISA, PMDA, NMPA)

EHS体系通过PSCI审查及多方体系认证：ISO14001, 45001, EcoVadis (Silver)等；

Passed PSCI's EHS inspection and certified in multiple systems, such as ISO14001, 45001, EcoVadis (Silver), etc.

一流的研发团队、设备、多样化的技术平台

First-Class R&D Team, Equipment, and Diversified Technology Platform

研发、生产、注册申报经验丰富的技术团队；

Technical Team Experienced in R&D, manufacturing, and registration;

善于利用各种新的合成技术手段解决原料药或起始物料、中间体工艺路线长，成本高，工艺复杂，周期长等问题，包括流体化学、酶催化、光化学、金属催化偶联等平台；

Experienced at solving problems such as long synthesis route, high cost of goods, complex synthesis, and long cycle of API or starting materials and intermediates using various novel synthesis techniques, including technology platforms such as flow chemistry, biocatalysis, photoredox reaction, metal catalyzed coupling reactions, etc.

口服制剂、各类特色制剂平台，解决化合物难溶或者稳定性差问题，多种缓控释，多种剂型研发和生产解决方案。

Providing oral drug product formulation and other drug product technology platforms, solving the problem of insoluble compounds or poor stability, and providing a variety of controlled releases, formulation development, and manufacturing solutions.

原料药CDMO服务

API Services

为全球合作伙伴提供临床前到商业化阶段的原料药一体化服务

We offer integrated services to worldwide partners for small molecule Active Pharmaceutical Ingredients (API), from pre-clinical to commercial supply.

工艺路线开发服务
Process Development

生产服务
Manufacturing

工艺安全评估服务
Process Safety Assessment

原料药技术平台

API Technology Platform

危险化合物
Hazardous Chemistry
绿色化学工艺
Green Chemical Process
手性化学
Chiral Chemistry

氢化
Hydrogenation
微粉化
Micronization
流体化学
Flow Chemistry

酶催化
Enzymatic Reaction
光化学
Photoredox Reaction
金属催化偶联
Metal Catalyzed Coupling Reactions

制剂CDMO服务

Drug Product Services

提供从临床前到临床2期阶段的制剂研发及生产服务

We provide formulation development and production services from preclinical to clinical phase II

临床前研究服务
Pre-formulation Study

临床制剂开发服务
Clinical Formulation Development Service

制剂生产服务
Drug Product Manufacturing

制剂技术平台

Drug Product Technology Platform

生物利用度增强递药
Bioavailability Enhancement Drug Delivery

缓控释递药
Control Released Drug Delivery

复杂注射剂递药
Complex Injectable Drug Delivery

儿童给药
Pediatric Drug Delivery

分析服务

Analytical Services

为全球客户提供全方位的药物分析服务。

We provide a full range of pharmaceutical analysis services to global clients.



API分析服务
API Analysis Service

临床前制剂分析服务
Pre-formulation Analysis Service

制剂分析服务
Drug Product Analysis Service

稳定性研究服务
Stability Study

数据完整性
Data Integrity

支持服务

Support

拥有一支经验丰富的注册团队，为全球客户提供CMC申报资料撰写、全球申报注册支持等服务。

We have an experienced registration team to provide global clients with CMC filing, global filing registration support, and other services.

CMC注册支持
Global CMC
Filing

项目管理
Project
Management

产品生命
周期的管理
Product Lifecycle
Management

EFS投资孵化业务

EFS Investment & Incubation Business



215 条

孵化公司产品管线
Pipelines in Total



91 家

孵化投资公司
Portfolio Companies

维亚生物创新中心（VBI）是维亚生物投资孵化和服务换股权（EFS）业务的核心部门，专注于发现、投资高潜力生物医药初创公司，以EFS（服务换股权）的形式解决未满足的临床医学需求，持续构建生物医药创新的开放式合作平台和共赢生态圈。

Viva Biotech combines conventional cash for service (CFS) and unique equity for service (EFS) business models, maintaining steady cash in flow from short-term drug discovery services while realizing massive revenue from long-term investments in drugs incubation. As the investment division of Viva Biotech Holdings (1873.HK), we are committed to being a collaborative platform for Innovative Biotech companies from around the world.

我们的投资策略 Our Investment Strategy



突破性的创新理念 Groundbreaking Innovation

您的“想法”要独特，并解决尚未满足的医疗需求或克服技术挑战
The "idea" needs to be differentiated and address true unmet medical need or technological challenges.



强大的团队 Strong Team

创始人和管理团队应具有较好的诚信度、公司建设业绩和广泛的医疗行业经验
The founder and management team should have strong integrity, a track record of company building, and broad experience in drug R&D.



商业可行性 Commercial Viability

未来5-10年能让患者群体受益和具备强大的市场潜力
There must be significant patient impact and strong market potential 5-10 years in the future.




战略契合 Strategic Fit

我们重点投资早期项目，并倾向于以投资现金和实物服务相结合的模式为您提供帮助
Our focus is early-stage therapeutics with a preference to invest in a combination of cash and in-kind services for each company.

持续优化的生物医药创新生态圈 Our Ecosystem

维亚推出了年度高峰会、Demo Day等系列活动，旨在为维亚孵化企业搭建一个开放、创新的平台，不断推动和参与医药创新生态圈的建立，希冀通过广泛合作建立良好的生态系统，实现多方共赢。

VBI continues building and optimizing the biomedical ecosystem while enhancing open cooperation platforms. Viva Biotech launched activities like the Annual Partnership Summit and Demo Day to encourage an open, creative atmosphere for Viva incubators.



专业的投后管理支持

Our Advantages – Optimized Incubation Platform

根据新药研发及公司成长阶段各类需求，提供投资并不断优化含研发、场地和后勤支持、产业对接、投融资等一系列投后增值的平台化服务，加速实现新药研发“从0到1”转化及商业化进程。

Viva BioInnovator works with some of the world's brightest minds to help discover novel and life-changing therapeutics. We can assist our portfolio companies through several avenues, including CRO services, financial support, access to experts, industry networks, back-office operations, and more. We continuously seek innovative ideas and set no restrictions on the indication, drug type, or company location.

CRO及CDMO服务

CRO & CDMO Services

技术领先的CRO平台，提供高效服务
Our leading CRO platform is productive and efficient

小分子药物研发、生产一站式CDMO服务
One-stop solution for small molecule drug CDMO

产业关系网

Industry Network

协助调动内部或外部资源（VC, MNC, CDMO）
Assistance in procuring internal or external resources (MNC R&D, B&D)

市场动态变化预警
Will alert founders to changes in market dynamics

专家支持

Experts

业务合作伙伴（业务运营和合规专家）
Business Partners (experts in business operation and compliance)

科学顾问（科研和药物开发专家）
Venture Advisors (experts in science and drug development)

资金

Capital

专注于种子轮和A轮融资
Average time to invest: 2 months

提供后期融资及财务支持
Introductions for later-stage funding and financial advice

运营

Operation

实验室和办公室位于上海、嘉兴、成都、杭州等多个城市
Lab and office locations in Shanghai, Jiaxing, Chengdu, Hangzhou, Boston, San Diego, etc.

提供人力资源、会计、采购、商业拓展、融资等多方位支持性服务
“Back-office” support (HR, Accounting, Procurement, BD, Financing, etc.)

已孵化企业速览

Overview of Portfolio Companies

| 肿瘤 Oncology | 代谢类疾病 Metabolic | 免疫类疾病 Immune | 中枢神经疾病 CNS |
|--|--|---|--|
| ANJI PHARMA Iteiron Elgia Therapeutics AeoL DOGMA saverna KARMA SORIAN Ribogenics MEBIAS DISCOVERY VersaPeutics Siku Pharma Triumvirid SYNTHIS TABOMEDEX BIOSCIENCES ArthroSi FORKHEAD A1 ExplorerBio MEDIAN FUSEBIO evecxia ophidion AmacaThera Lotario Poniva flash therapeutics seraxis Livati ANTAR Calira Ornovi IpiNovyx L-MAB VINCERE Regenacy Bonti FS Therapeutics DEKA EubulusBio i2 THERAPEUTICS Blue Oak Peb Therapeutics QurAlis AcureStem EXARTA THERAPEUTICS ARGONAUT Focus-X | APEIRON CYBREXA Amberstone ALETA DOMAIN THERAPEUTICS GP PHENOMICAL TeLO KMT NAKI THERAPEUTICS regla gene grove BIOPHARMA ABMTX NERIO THERAPEUTICS | ARREPATH PWIN LANTERNS BRIGHT ANGEL VIVAVISION FULLCIRCLES DT PHARMA MorphoGene TECHNODERMA XLEMEN United Inocell BIOCAST | Basking Biosciences RIPARIAN PHARMACEUTICALS Trio Bio HAYA Therapeutics |
| 传染性疾病 Infection | 眼科疾病 Ophthalmic | 心血管疾病 CVD | 其他 Others |

商业道德准则

Business Conduct and Ethics

维亚生物高度重视并保障客户的数据信息安全和知识产权；持续完善质量管理体系；始终秉持诚实守信、合法合规、廉政自律的商业道德精神；严格遵守环境管理制度。

Viva Biotech attaches great importance to protecting client information and intellectual property. We continuously optimize the quality management system, we always uphold the business ethics of honesty and trustworthiness, legal compliance and integrity, and we strictly comply with laws and regulations related to corporate governance and the Corporate Governance Code. In addition, we strictly comply with the environmental management systems.

数据保护和隐私安全

Information Security Management

维亚生物高度重视客户信息和商业机密保护，严格遵守关于信息安全与隐私保护的相关规定，建立了信息安全小组和严格的信息管理制度规范及计算机信息安全管理制度。

Viva attaches great importance to protection of customer information and trade secrets. In strict compliance with the relevant regulations on information security and privacy protection, the Group has established an information security team, strict information management system, and computer management system.

知识产权保护

Protection of Intellectual Property Rights

知识产权是维亚生物创新发展的不竭源泉。维亚生物严格遵守相关法律法规，制定并严格执行《知识产权保护措施流程》。在CDMO生产阶段建立完善的保密体系，充分尊重客户的知识产权和机密信息。

Intellectual property rights constantly empower Viva Biotech's innovation and development. Viva firmly implemented the Intellectual Property Rights Protection Measures, strictly following the Patent Law of the People's Republic of China and the Trademark Law of the People's Republic of China. During CDMO business processes, Langhua is committed to protect customer's confidential information and Intellectual Property strictly.

质量管理体系

Quality Management System

维亚生物始终持续关注服务质量的有效提升，严格遵守相关法律法规，并已获得了ISO9001:2015质量管理体系认证。在CDMO生产阶段严格遵守cGMP和ICH要求，保持良好的审计记录。

Viva Biotech has always paid close attention to effective service quality improvement. The Group strictly abides by relevant laws and regulations and has obtained ISO 9001:2015 quality management system certification. During CDMO business processes, Langhua complies with cGMP & ICH Guideline and maintains good track record.

合规与商业道德

Compliance and Business Ethics

维亚生物秉持诚实守信、合法合规、廉政自律的商业道德精神，严格遵守企业管治相关法律法规以及《企业管治守则》，对贿赂、勒索、欺诈、洗黑钱等行为零容忍。

Viva Biotech upholds the business ethics of honesty and trustworthiness, legal compliance, integrity, and self-discipline, acts in strict accordance with relevant laws and regulations on corporate governance and the Corporate Governance Code, and demonstrates zero-tolerance for bribery, extortion, fraud, and money laundering.

EHS管理体系

EHS System

维亚将可持续发展理念融入集团日常运营中，落实减少温室气体排放的企业责任。在CDMO生产阶段建立基于ISO14001、ISO45001和国内安全生产标准的EHS管理体系，确保环保、健康、安全。

Viva adheres to sustainable development in daily operations and takes corporate responsibility very seriously for reducing greenhouse gas emissions. During CDMO business processes, Langhua established the EHS system following the requirement of ISO 14001, ISO 45001 and applicable national law and standards.

■ 助力创新药研发及生产，赋能全球合作伙伴

Facilitating the R&D and Production of Innovative Drugs and Empowering Global Partners

技术领先

Advanced Technology

技术平台具有国际领先水平
World-leading Technology Platform

技术得到充分验证，有很多成功案例
Proven technology with numerous successful cases

合作方式灵活

Flexible Cooperation

FTE，FFS及风险共享多种模式，适应客户不同课题
FTE (Full-Time Equivalent), FFS (Fee-for-Service), and Risk Sharing- Various models to adapt to different clients' needs

一流的服务质量

First-Class Service

良好的客户沟通
Good communication

及时的报告研究结果
Timely reporting of research results

帮助客户解决研发困难与问题，提供解决方案
Help clients solve R&D difficulties and provide solutions

综合性服务平台

Comprehensive Service Platform

研发到生产的全流程服务公司
A wide-ranging service company from R&D to production

早期研发各种技术的综合应用平台
A comprehensive application platform with various early R&D technologies

综合性生产工艺和制剂工艺研究开发平台
R&D platform for comprehensive production and formulation processes

国际化专业管理团队

International Professional Management Team

管理层基本具有十年以上海外留学工作经验
The management team has more than ten years of overseas study and work experience

管理团队熟悉创新药研发技术与流程，创新药研发管理经验丰富
The management team is familiar with innovative drug R&D technology and processes, and has rich experience in innovative drug R&D management

专注创新 诚信敬业

INNOVATION, INTEGRITY AND PROFESSIONALISM

数据截止至2022.12.31
Data updated until 2022.12.31



2,076 家

客户数量总计

Biotech and pharmaceutical clients worldwide



2,601 人

全球员工数量

Employees worldwide



66 个

国内外专利数

Domestic and foreign patents



91 家

投资企业数量

Invested and incubated companies

分布在上海、嘉兴、苏州、杭州、宁波、台州、成都等城市，有效分散风险
Distributed in Shanghai, Jiaxing, Suzhou, Hangzhou, Ningbo, Taizhou, Chengdu, and more to effectively diversify risks



上海周浦



浙江宁波



四川成都



浙江嘉兴



浙江杭州

成就客户 合作共赢

CUSTOMER SUCCESS, WIN-WIN COOPERATION

成为全球创新型生物研发公司长期的合作伙伴

To Become a Long-Term Partner for Global Innovative Biotech Companies



联系我们

邮箱: info@vivabiotech.com

官网: <https://www.vivabiotech.com>